Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Guanyl hydrazones are emerging as valuable, target-tunable functional groups. In particular, aryl guanyl hydrazones, owing to extensive conjugation with aromatic rings, exhibit lower p values compared to their aliphatic counterparts, so that, at physiological pH, a substantial proportion of them remains in a nonionized or partially protonated form, thereby increasing their lipophilicity and enhancing BBB permeability. Intriguingly, their tautomeric equilibria provide flexible charge allocation, adapting to binding site demands for protein and nucleic acid target species. Herein, (hetero)aromatic drugs, clinical candidates, leads and hits bearing one or more guanyl hydrazones are presented in terms of mechanism of action, and potency. Synthetic access to guanyl hydrazone-containing molecules, through complementary and simple routes, is briefly presented. Future trends for aryl guanyl hydrazones in CNS and PNS drug discovery are critically discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333022 | PMC |
http://dx.doi.org/10.1021/acschemneuro.5c00463 | DOI Listing |